1300022I university of maryland, baltiomore; vteu; to FY.2017.B8C12.0080--22 task area b-c phase II vaccine trial for influenza; H7N9 flu can 8030247; $4,678,871
Ended Awarded Last action
- Contract number
- HHSN27200021
- Awardee
-
University Of Maryland, Baltimore UEI Z9CRZKD42ZT1 Part of University System Of Maryland
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,522,739
Award facts
- Opportunity
-
- NIAIDDMIDNIHAI2012144 Solicitation number
- Vaccine and treatment evaluation units (vteu) Award Notice · Posted Mar 29, 2012
- Contract value 64% obligated
-
- $4,522,738.93 Current, with exercised options
- $7,069,800.93 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Baltimore, MD 21201, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | -$156,132 | |
| Other Administrative Action | $0 | |
| Original award | $4,678,871 |
About this award
This $4,678,871 cost-no-fee delivery order contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to the University of Maryland, Baltimore (UMB) for Task Area B-C Phase II Vaccine Trial for Influenza H7N9. The contract is part of the Vaccine and Treatment Evaluation Units (VTEU) program, a major NIH biomedical research initiative, and has a potential total value of $7,069,800.93. This non-set-aside award tasks UMB with conducting clinical trials to evaluate influenza vaccines, a critical component of pandemic preparedness efforts. UMB will collaborate with Case Western Reserve University as a subcontractor on the study design and protocol development. The contract has a period of performance through September 30, 2024.
Quick answers
Who was awarded contract HHSN27200021?
HHSN27200021 was awarded to University Of Maryland, Baltimore by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 27, 2017.
How much is contract HHSN27200021 worth?
The government has obligated $4,522,739 on HHSN27200021. Its potential value, with all options, is $7,069,801.
Is contract HHSN27200021 an order under another contract?
Yes. HHSN27200021 is a delivery order under HHSN272201300022I, an indefinite delivery contract, on Vaccine and Treatment Evaluation Units (VTEU).
Was contract HHSN27200021 competed?
The extent of competition for HHSN27200021 was full and open competition. The government received 9 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award